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Abstract
Juvenile idiopathic arthritis (JIA) is the most common joint disorder in developing
children. Juvenile idiopathic arthritis is difficult to diagnose and treat. In some
patients, signs and symptoms can be frustratingly inconsistent, contradictory
or idiosyncratic. Short stature in patients with JIA is usually due to reduced
growth in the lower extremities, and only rarely due to reduced growth in the
spinal column. In some studies, children with JIA were found to have infantile
body proportions. Puberty is delayed in children with JIA. In children with chronic
arthritic disorders, there is a strong correlation between the activity of the
disease and the age of puberty. The main goals in reducing growth retardation
in children with JIA are promoting timely remission and reducing the duration
and dosage of corticosteroid treatment. It is important to regularly monitor
physical development. Further improvements to the treatment protocol depend
on continued interdisciplinary research involving paediatricians, rheumatologists
and clinical anthropologists.
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Introduction
Juvenile idiopathic arthritis (JIA) is the most common joint disorder in
developing children [1]. The incidence of JIA is between 6 and 19 per
100,000 with a prevalence of about 1 in 1000. The condition is slightly more
common in females [2].
Juvenile idiopathic arthritis is difficult to diagnose and treat. In some
patients,  signs  and  symptoms  can  be  frustratingly  inconsistent,
contradictory or idiosyncratic. In JIA, the clinical picture and course of
inflammation vary considerably, and are different than in inflammatory
conditions of the joints in adults [3]. Furthermore, the symptoms differ
from patient to patient, and also change over the course of the disease.
There are few reliable serological manifestations.
The classification of diseases accompanied by joint inflammation has
been frequently revised. According to the criteria proposed by the
International League against Rheumatism, JIA refers to inflammation of
the joints in persons under 16 years old that lasts for at least 6 weeks [1].
Clinically, JIA can be divided into seven subtypes [4]:
• systemic,
• persistent oligoarticular,
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• extended oligoarticular,
• polyarticular with positive rheumatoid factor (RF),
• polyarticular with negative rheumatoid factor (RF),
• psoriatic arthritis, and
• arthritis related to enthesitis.
The  name  juvenile  idiopathic  arthritis  has
replaced previously used names such as juvenile
chronic arthritis (JCA), which had been proposed by
the European League against Rheumatism, and
juvenile rheumatoid arthritis (JRA), which had been
proposed by the American College of Rheumatology
[5, 6].
Growth disturbance
Juvenile idiopathic arthritis is characterized by
chronic inflammation in various tissues of the body,
and  can  affect  joints,  ligaments,  muscles  and
internal organs. Over the long term, inflammation
can  cause  stiffening  and  deformation  of  the
affected joints, and can lead to significant growth
retardation [7, 8]. Growth retardation can result in
severely reduced body stature, which is defined as
body height in the lowest third percentile of the
population, or body height more than two standard
deviations below the mean for the population.
The  proportion  of  children  with  JIA  that  are
abnormally short ranges from 10 to 40% [9, 10].
Growth retardation is significantly more severe in
children with the systemic subtype of the disease
and in children in whom many joints are affected 
[9, 11]. Growth retardation is also more severe in
children with extensive joint damage than in children
with early or moderate anatomical changes [7, 12].
Factors responsible for growth retardation in
chronically ill children include frequent infections,
primary and secondary malnutrition, long-term
stress related to being chronically ill or handicapped,
and side effects of therapy. It is often difficult to tell
how much growth retardation can be attributed to
the disease itself, and how much to the side effects
of treatment [13].
Growth  retardation  in  children  with  JIA  is
especially severe when auto-immunological activity
has been elevated over a long period, which is
associated with high levels of the pro-inflammatory
cytokines  IL-1,  IL-6  and  TNF-α [7,  14].  These
cytokines reduce secretion of growth hormone from
the pituitary gland, and also act directly on the
growth plates of the long bones [15, 16].
In laboratory experiments, IL-1 and TNF-α have
been found to reduce proliferation and differentiation
in chondrocytes in the growth plates, to induce death
in chondrocytes, and to disrupt the synthesis of type II 
collagen and proteoglycans [17, 18].
Inflammation also hampers blood circulation in
the affected joints, which limits the supply of
oxygen and nutrients to the growth plates of the
long bones. At first, there is an increase in the rate
of bone formation in the vicinity of the affected
joint.  However,  if  auto-immunological  activity
persists for a long time, cell proliferation in the
growth  plates  ceases  before  development  is
complete, and the length of the limbs is likely to be
irreversibly  affected  [18].  Effective  and  timely
treatment can preserve growth potential in children
with JIA, thereby allowing bone growth to catch up
[8, 10].
Short stature in patients with JIA is usually due
to reduced growth in the lower extremities, and
only rarely due to reduced growth in the spinal
column [19, 20]. In some studies, children with JIA
were found to have infantile body proportions [12,
19]. In one study, however, no abnormalities in body
proportions were found [9]. The authors reported
that reduced subischial leg length did not affect
body proportions in children with JIA because it was
proportional  to  the  general  reduction  in  body
stature.
In experiments on the level of physical develop-
ment in children with JIA, not only was the length
of the lower extremities significantly reduced, but
the proportions of the chest were also affected
[12]. Chest width and chest capacity were both
reduced.
Children with JIA are more easily exhausted by
physical exertion because they are generally less
physically active and experience pain related to the
disease [21]. The capacity for physical exertion was
particularly reduced in children with an active form
of the disease and in children with many affected
joints. Because children with JIA are frequently less
physically active, muscle development is affected,
which further contributes to the abnormal con-
struction of the chest [21].
Another factor that reduces growth in children
with JIA is long-term treatment with corticosteroids,
which is usually administered to children with the
systemic and polyarticular forms of the disease.
Corticosteroids are usually administered when other
drugs fail to bring about remission of the disease
[6, 10].
Corticosteroids affect growth in many ways. High
levels of corticosteroids stimulate the release of
somatostatin,  inhibit  the  release  of  growth
hormone, insulin growth factor-1 (IGF-1) and IGF
binding  protein,  decrease  the  expression  of
receptors  for  growth  hormone  and  IGF-1,  and
reduce the level of IGF binding protein [22]. High
levels of corticosteroids can also reduce proliferation
in growth plate chondrocytes by inhibiting the
expression of receptors for growth hormone and
IGF-1. Furthermore, corticosteroids interfere with
normal bone development by increasing the level
of proteolysis in nearby muscle tissue [23].
The effect of corticosteroids on growth has been
confirmed in short-term and longitudinal studies.Arch Med Sci 1, February / 2010 21
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In studies carried out using knemometry, the rate
of growth in the lower extremities was reduced in
children  treated  with  corticosteroids,  as  was
metabolic turnover in the bone tissue [24].
In one study on children with JIA, long-term
treatment with corticosteroids irreversibly reduced
terminal body height, whereas treatment lasting
less than one year had no effect. The effect did not
depend on the dosage administered [7].
On the other hand, in a longitudinal study on
pre-pubertal  children  with  juvenile  idiopathic
arthritis who were treated with corticosteroids,
growth rate was significantly reduced only during
the first year of treatment, after which it increased.
This was attributed to an improvement in the
course  of  the  disease,  to  the  low  dosages  of
corticosteroids used, and to the fact that the course
of the disease was carefully monitored [11].
Final growth parameters are not always reduced
in  patients  suffering  from  juvenile  idiopathic
arthritis. In some children, catch-up growth is
possible when the disease is in remission or when
corticosteroid treatment is interrupted. In this case,
final growth parameters can approach and even
reach normal levels. This is especially true for
children that are younger, and thus have been
suffering from the disease for a shorter time [25].
In one study on children with juvenile idiopathic
arthritis, catch-up growth was reported in 70% of
the subjects examined. On the other hand, growth
retardation was irreversible in the other 30%, in spite
of the fact that these children did not differ from the
others in terms of duration of the disease activity
or the dosage of corticosteroids administered. This
was attributed to differences in the genetic potential
for growth among the subjects [25].
Not all studies have confirmed a connection
between the degree of growth retardation and the
dosage of corticosteroids administered. However,
it is generally believed that prednisone at a dosage
of 0.25 mg/kg/day can affect growth [7, 8, 14].
Another factor responsible for growth retardation
is malnourishment, which is frequently seen in
children with JIA. In some cases, malnourishment
can be severe enough to induce cachexia [26-28].
Malnourishment in children with JIA is caused by
many  factors.  High  levels  of  pro-inflammatory
cytokines can reduce energy uptake and meta-
bolism, even if the patient is on an appropriate diet.
Energy intake in children with JIA is negatively
correlated with IL-1 production [26]. Malnourishment
is also more common in children with inflammation
of the maxillo-mandibular joint, and in children in
whom the digestive tract is affected to the point
that  nutrient  assimilation  is  reduced.  Coeliac
disease, for example, is about seven times more
common in children with JIA than in the general
population [29]. Many of the drugs used in treating
the disease can also cause disturbances of the
gastro-intestinal tract. This is particularly true for
methotrexate [27].
Delayed puberty
Sexual development is also delayed in children
with JIA. In children with chronic arthritic disorders,
there is a strong correlation between the activity of
the disease and the age of puberty [30-32]. In girls
with JIA, menarche occurs almost two years later
than in healthy children. In boys, puberty is delayed
because testosterone production by the testicular
Leydig cells is reduced [33].
On the other hand, in a study on twenty-four
year old women who had suffered from JIA during
childhood, menarche was found to have occurred
on average at age 13, which is about the same age
as in healthy individuals [34]. There was also no
significant difference between the women and their
healthy  peers  in  terms  of  fertility,  although
fecundity was significantly reduced. The women
had a higher incidence of gynaecological disorders,
and were more likely to miscarry [34].
Treatment goals and pharmaceutical agents
The main goals in reducing growth retardation
in children with JIA are promoting timely remission
and reducing the duration and dosage of corti-
costeroid treatment. Clinical symptoms can be
improved and inflammation can be controlled by
administering intra-articular corticosteroids, metho-
trexate, immuno-suppressing drugs and biological
agents [3, 6].
Long-acting corticosteroids such as triamcinolone
(Hexatrione), Depo-Medrol and Diprophos can be
injected directly into the affected joints in patients
with chronic or recurrent inflammation [3]. No more
than three or four doses should be injected into 
a single joint. This method is particularly useful in
cases  of  oligoarticular  arthritis  because  corti-
costeroids are administered locally, not systemically.
This often reduces the risk of side effects associated
with systemic treatment [35-38].
Methotrexate is a folic acid antagonist. In one
study, methotrexate was administered to children
under ten years old with either oligoarticular or
polyarticular onset JIA [39]. The study group consisted
solely  of  children  who  had  not  received  corti-
costeroids during the previous year. After one year
of treatment with methotrexate, the children were
responding positively to treatment. The number of
affected joints was reduced by half. Growth rate was
significantly improved, and body height was higher
in children who responded positively to treatment
than in children who did not respond [39]. On the
other hand, methotrexate was less effective in
children with the systemic form of the disease [40].22 Arch Med Sci 1, February / 2010
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Children receiving methotrexate may require folic
acid  supplements.  The  dosage  of  folic  acid
administered should be individually tailored to the
patient’s needs [41].
Etanercept and other TNF-α antagonists reduce
inflammation and make it possible to use more
conservative doses of corticosteroids [42, 43].
Etanercept has been found to improve the rate of
growth in pre-pubertal and pubertal children [44].
Long-term  studies  are  needed  to  confirm  the
benefits of TNF-α antagonists, and to determine
the importance of negative side effects such as
increased frequency of infectious disorders [45].
Infliximab is a monoclonal antibody that binds
TNF-α. Preliminary reports of small-scale studies
have been promising, although full-scale randomized
placebo-controlled studies are needed to confirm
the effectiveness and safety of the drug [46].
Adalimumab is a human monoclonal antibody
that binds TNF-α, and has also been used to treat
JIA. In a study on 171 patients between four and
seventeen years old with oligoarticular JIA, ada-
limumab was administered alone or in combi-
nation  with  methotrexate.  Adalimumab  was
found to be very effective and to have relatively
few side effects such as headaches, respiratory
tract infections, and pain and reddening at the
site of injection [47].
Anakinra is an IL-6 receptor antagonist. Preli-
minary testing has indicated that it rapidly improves
the clinical state and laboratory test results of
children with systemic JIA, with noticeable positive
effects after only two weeks of treatment [46, 48]. 
Tocilizumab is another IL-6 receptor antagonist
that has proven effective in treating systemic JIA.
In  a  study  on  56  patients  between  two  and
nineteen years old, treatment with tocilizumab
resulted in sustained clinical improvement and had
a favourable risk-benefit profile [49].
Abatacept  and  atlizumab  are  among  the
biological preparations that are currently in the
clinical trial phase. Abatacept is a fusion protein
that blocks the activation of T lymphocytes. Atli-
zumab is an IL-6 receptor antagonist [46].
Growth hormone is also being evaluated for use
in children with JIA who have received long-term
corticosteroid treatment. In one study, regular
administration of growth hormone over several
years improved growth rate, although the effect on
terminal body height was less than expected. There
was also an increase in serum IGF-1 and IGF binding
protein levels, and a reduction in the proportion of
adipose tissue [10].
In another study, growth hormone was admi-
nistered to pre-pubescent children. The children
were then observed for four years, during which
time  growth  rate  was  significantly  improved.
Treatment was more effective in children with
milder symptoms than in children with more active
forms of the disease [50].
The  major  disadvantage  of  treatment  with
growth hormone is an increased risk of neoplastic
disorders and scoliosis [41]. The exorbitant cost of
treatment also limits its general use in minimizing
growth retardation in children with JIA [8].
Conclusions
At the present time, the most effective way to
reduce growth retardation in children with JIA is to
control inflammation with the help of currently
available drugs, while reducing the duration and
dosage of treatment with corticosteroids. It is also
important to regularly monitor physical development.
Further improvements to the treatment protocol
depend  on  continued  interdisciplinary  research
involving paediatricians, rheumatologists and clinical
anthropologists.
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